ReproCELL Incorporated (4978.T)

JPY 103.0

(0.0%)

Market Cap (In JPY)

9.7 Billion

Revenue (In JPY)

2.42 Billion

Net Income (In JPY)

-31.41 Million

Avg. Volume

741.8 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
100.0-180.0
PE
-
EPS
-
Beta Value
0.298
ISIN
JP3974770004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Shuji Yokoyama Ph.D.
Employee Count
-
Website
https://www.reprocell.com
Ipo Date
2013-06-26
Details
ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.